learning and memory in animal models: nootropics and compounds | sci-wiki

AC-260584

AC-260584 is an Abbott Laboratories research compound from the 2000s, part of the same M1-muscarinic-agonist wave as sabcomeline and xanomeline but never carried past the tool-compound stage. It was designed as an orally bioavailable, functionally selective M1 agonist that improved cognitive performance in animal testing while sidestepping the receptor subtypes responsible for the GI and cardiac side effects that plagued earlier muscarinic drugs. Unlike some of its contemporaries, AC-260584 does not appear to have been pushed into human trials; its public record is essentially one core pharmacology paper, making it a compound that lives almost entirely in the preclinical literature.

reference

Nootropic

Besipirdine

Besipirdine was Hoechst-Roussel's attempt to broaden the cholinergic-hypothesis playbook for Alzheimer's disease by hitting two neurotransmitter systems at once, enhancing both cholinergic and noradrenergic transmission rather than acetylcholine alone, on the theory that a dual mechanism might outperform pure cholinesterase inhibitors. In a 275-patient trial, patients on besipirdine held steady on cognitive testing over three months while the placebo group declined, a genuinely encouraging signal for a still-experimental Alzheimer's drug in the mid-1990s. That promise collapsed in Phase III, where a subset of patients developed serious cardiovascular side effects, forcing Hoechst-Roussel to abandon the program; the company had also explored besipirdine for other indications, including multiple sclerosis-related walking impairment, but none of it reached market.

reference

Nootropic

Linopirdine

Linopirdine took a completely different route to boosting acetylcholine than anything else in this collection; instead of blocking the enzyme that breaks ACh down, DuPont built it to block KCNQ2/KCNQ3 potassium channels, the so-called M-channel, which in turn triggers broad neurotransmitter release, acetylcholine included, across the brain. Preclinical work in the late 1980s looked strong enough that DuPont pushed it into Alzheimer's clinical trials, but the results in patients were equivocal; the drug needed high doses to meaningfully block the M-current, and those doses caused cholinergic overstimulation side effects like tremor. The program was ultimately discontinued, but linopirdine's real legacy is scientific rather than commercial, it became the founding tool compound for an entire generation of KCNQ channel research, directly enabling more selective descendants like XE-991 and eventually helping validate KCNQ as a target that led to the anticonvulsant retigabine.

reference